Curileum Discovery Ltd is a biotechnology company based in London that focuses on early intervention in the development of serious gastrointestinal diseases. With a team of dedicated scientists, they specialize in discovering and developing novel therapeutics to correct cell production in the continuously regenerating mucosal barrier of the gut. Their mission is to identify regulators that drive healthy cell production, particularly in high-risk patients for bowel cancer and those suffering from chronic painful gut inflammation associated with inflammatory bowel disease (IBD) such as Crohn's disease.

Led by Dr. Jeff Moore, an experienced scientist with a background in regulating cell production, Curileum has made significant breakthroughs in the field. They have developed a small molecule to reduce polyp formation and progression to bowel cancer, as well as a stem cell therapy to repair an incurable condition in Crohn's disease patients.

With their cutting-edge research and commitment to translating scientific discoveries into game-changing therapies, Curileum is at the forefront of revolutionizing the treatment of gastrointestinal diseases